Latest Prostate Specific Antigen News
Shows the strongest correlation between biochemical recurrence and subsequent systemic progression.
The odds of developing lethal prostate cancer were increased by 6.9 to 12.6 times for men aged 40 to 59 years with higher PSA values.
LUTS is 49% more likely to develop in men with a PSA level above 6 ng/mL versus 4 ng/mL or less.
The PLCO trial's conclusion that routine PSA testing does not affect prostate cancer mortality risk could be wrong.
The odds of PSA screening were higher among blacks than non-Hispanic whites.
PSA level declined by an average of 0.68 ng/mL in the treatment group.
Older men whose clinician was a physician trainee had substantially lower prostate-specific antigen (PSA) screening rates.
The proportion of biopsied men who have complications from the procedure rose from 14% to 18% from 2005 to 2014.
This includes less frequent screening and more restrictive biopsy referral criteria.
Differential effect of 2012 USPSTF recommendations for primary care providers, urologists.
Rate of unnecessary screening was 15.7% in men 65 years and older.
Prostate cancer is 1.4 times more likely to develop in those with a PSA level of 2.5 ng/mL or higher.
Equal serum prostate-specific antigen and prostate-specific antigen mass despite larger prostates.
A 50% or greater PSA decline at 15 days after start of treatment was associated with increased progression-free and overall survival.
Prostate-specific antigen density, total tumor length are significant predictors.
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)